TY - JOUR
T1 - Optimal use of bendamustine in hematologic disorders
T2 - Treatment recommendations from an international consensus panel-An update
AU - Cheson, Bruce D.
AU - Brugger, Wolfram
AU - Damaj, Gandhi
AU - Dreyling, Martin
AU - Kahl, Brad
AU - Kimby, Eva
AU - Ogura, Michinori
AU - Weidmann, Eckhart
AU - Wendtner, Clemens Martin
AU - Zinzani, Pier Luigi
N1 - Publisher Copyright:
© 2015 The Author(s). Published by Taylor & Francis.
PY - 2016/4/2
Y1 - 2016/4/2
N2 - Bendamustine has achieved widespread international regulatory approval and is a standard agent for the treatment for chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma and multiple myeloma. Since approval, the number of indications for bendamustine has expanded to include aggressive non-Hodgkin lymphoma and Hodgkin lymphoma and novel targeted therapies, based on new bendamustine regimens/combinations, are being developed against CLL and lymphomas. In 2010, an international panel of bendamustine experts met and published a set of recommendations on the safe and effective use of bendamustine in patients suffering from hematologic disorders. In 2014, this panel met again to update these recommendations since the clarification of issues including optimal dosing and management of bendamustine-related toxicities. The aim of this report is to communicate the latest consensus on the use of bendamustine, permitting the expansion of its safe and effective administration, particularly in new combination therapies.
AB - Bendamustine has achieved widespread international regulatory approval and is a standard agent for the treatment for chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma and multiple myeloma. Since approval, the number of indications for bendamustine has expanded to include aggressive non-Hodgkin lymphoma and Hodgkin lymphoma and novel targeted therapies, based on new bendamustine regimens/combinations, are being developed against CLL and lymphomas. In 2010, an international panel of bendamustine experts met and published a set of recommendations on the safe and effective use of bendamustine in patients suffering from hematologic disorders. In 2014, this panel met again to update these recommendations since the clarification of issues including optimal dosing and management of bendamustine-related toxicities. The aim of this report is to communicate the latest consensus on the use of bendamustine, permitting the expansion of its safe and effective administration, particularly in new combination therapies.
KW - Bendamustine
KW - CLL
KW - Hodgkin
KW - NHL
KW - multiple myeloma
UR - http://www.scopus.com/inward/record.url?scp=84961060183&partnerID=8YFLogxK
U2 - 10.3109/10428194.2015.1099647
DO - 10.3109/10428194.2015.1099647
M3 - Review article
C2 - 26592922
AN - SCOPUS:84961060183
SN - 1042-8194
VL - 57
SP - 766
EP - 782
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 4
ER -